April 19th 2024
This approval is the second biosimilar approval for manufacturer Alvotech.
Turning Food Allergy Triggers Into Therapy: A Managed Care Lens on Immunotherapy and Targeted Biologics
1.5 Credits / Immunology
View More
Individualizing Care for Patients With PIDD: The Role of the Pharmacist in Managing Patients on IVIg and SCIg
1.5 Credits / Immunology
View More
Understanding the Role of IVIg and SCIg for the Management of CIDP: Information the Pharmacist Needs to Know to Optimize Care, featuring a Patient Perspective
1.5 Credits / Immunology, Neurology
View More
Targeted Therapies for the Management of Eosinophilic Esophagitis Across the Life Cycle: The Role of the Pharmacist in Patient Identification and Optimization, featuring a Pat...
1.5 Credits / Immunology
View More
Discerning the Significant Burden of Prurigo Nodularis: The Role of Targeted Therapies in Improving Patient Quality of Life, featuring a Patient Perspective
1.5 Credits / Dermatology, Immunology
View More
Reducing the Clinical and Economic Burden of Managing CRSwNP With Emerging Targeted Therapies: A Review for Specialty Pharmacists, featuring a Patient Perspective
1.5 Credits / Immunology
View More
Reducing the Clinical and Caregiver Burden of Moderate to Severe Pediatric Atopic Dermatitis Through Improved Access to Treatments, featuring a Caregiver Perspective
1.5 Credits / Dermatology, Immunology
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Exploring Targeted Treatment Options for Hereditary Angioedema: Considerations for Pharmacists
1.0 Credit / Immunology
View More
Unveiling the Impact of Childhood Eczema: A Guide to Moderate-Severe Pediatric Atopic Dermatitis
1.0 Credit / Dermatology, Immunology
View More
Revolutionizing Pediatric Atopic Dermatitis Treatment With Targeted Biologics
1.0 Credit / Dermatology, Immunology
View More
Practical Approaches in the Management of Primary Immunodeficiency Disorders: Understanding the Role of Intravenous and Subcutaneous Immunoglobulin
1.0 Credit / Immunology, Rare Diseases
View More
Maximizing the Potential of Biologics in Moderate to Severe Pediatric Atopic Dermatitis: The Expertise of the Specialty Pharmacist
1.0 Credit / Dermatology, Immunology
View More
Managed Care Perspectives on the Burden of Food Allergies and Advances in Treatment
1.5 Credits / Allergy, Immunology
View More
Best Practices for Optimizing Biologic Therapy Management for Moderate to Severe Atopic Dermatitis in Children
1.5 Credits / Dermatology, Immunology
View More
Integrating Biologic Therapy Into Clinical Practice for the Management of Eosinophilic Esophagitis
1.5 Credits / Gastroenterology, Immunology
View More
Understanding the Burden of Eosinophilic Esophagitis in Children
1.0 Credit / Gastroenterology, Immunology
View More
The Expertise of the Specialty Pharmacist in Pediatric Eosinophilic Esophagitis
1.0 Credit / Gastroenterology, Immunology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Emerging Biologic Therapy for the Management of Eosinophilic Esophagitis in Children
1.0 Credit / Gastroenterology, Immunology
View More
Optimizing Inflammatory Bowel Disease Treatment: A Pharmacist's Guide to Biologics and Monoclonal Antibodies
1.0 Credits / Gastroenterology, Immunology
View More
Navigating the Complexities of Biologic Therapy for Moderate to Severe Atopic Dermatitis in Children: The Impact of Pharmacists on Patient Care
1.5 Credit / Dermatology, Immunology
View More
High Adherence, Low Adverse Events Reported Across Different Oral Disease-Modifying Therapies
April 21st 2021Research presented at Academy of Managed Care Pharmacy’s 2021 virtual conference evaluated tolerance and adherence to oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
Studies Reveal Positive Results for Infliximab Biosimilar
June 18th 2020In studies presented this month at the European E-Congress of Rheumatology 2020, investigators revealed positive findings for the infliximab biosimilar CT-P13 (Inflectra, Remsima), which is developed by Celltrion of Incheon, Republic of Korea.